Search

Your search keyword '"Bardet, S."' showing total 319 results
Start Over Author "Bardet, S."
319 results on '"Bardet, S."'

2. Reversible and irreversible effects of mild thermal treatment on the properties of wood used for making musical instruments: comparing mulberry to spruce

Author

Karami E, Bremaud I, Bardet S, Almeras T, Guibal D, Langbour P, Pourtahmasi K, and Gril J

Subjects
Anisotropy, CIELab, Morus alba, Musical Instruments, Reconditioning, Thermal Treatment, Forestry, SD1-669.5
Abstract

Thermal treatments can be considered as an accelerated ageing, bringing partly similar changes in properties as naturally aged wood. Thermal treatment was applied on white mulberry (Morus alba L.), a dominant species for making musical instruments from middle-East to Far-East, to investigate the effects on the vibro-mechanical and physical properties of this wood, and the results compared to previously published data on spruce (Picea abies Karst.) as a reference for the soundboard of Western string instruments. Thermal treatment (TT) at 150 °C and 0% of relative humidity was applied to five analogous groups of specimens with five different durations (2.5, 8, 24, 72, 261 hours). Humidity re-conditioning of specimens was done to explore the reversibility of TT effects. Physical and vibrational properties such as specific gravity (γ), equilibrium moisture content (EMC), CIELab colorimetric values, specific modulus of elasticity (E’/γ) and damping coefficient (tanδ) in longitudinal (L) and radial (R) directions, have been measured after stabilisation of samples in standard conditions (20 °C, 65% RH), before and after TT and then after re-conditioning. Untreated mulberry had a low EMC, very low L/R anisotropy and low E’L/γ, and relatively low tanδ. Weight loss (WL) and CIELab values evolved similarly during TT for mulberry and for previous results on spruce, however, their EMC and vibrational properties were affected differently. This could be explained in part by the low anisotropy of mulberry, and in part by its particular extractives. The parts of irreversible effects, linked to chemical modification or degradation, and of reversible effects, linked to physical configuration, were different between mulberry and spruce. The applied treatments did not bring permanent “improvements” in vibrational properties of mulberry, yet its colour appearance was enhanced.

Published
2022
Full Text
View/download PDF

7. TEP/TDM à la F18-choline ou TEMP/TDM au Tc99m-sestaMIBI en première intention pour la prise en charge chirurgicale de l’hyperparathyroïdie primaire : APACH2, une étude multicentrique de phase III

Author

Quak, E., primary, Lasne-Cardon, A., additional, Cavarec, M., additional, Lireux, B., additional, Bastit, V., additional, Roudaut, N., additional, Salaun, P.Y., additional, Keromnes, N., additional, Potard, G., additional, Vaduva, P., additional, Esvant, A., additional, Jegoux, F., additional, Crouy-Chanel, O., additional, Devillers, A., additional, Guery, C., additional, Lasnon, C., additional, Ciappuccini, R., additional, Sali Dauda, M., additional, Legrand, B., additional, Estienne, A., additional, Grellard, J.M., additional, Bardet, S., additional, and Clarisse, B., additional

Published
2023
Full Text
View/download PDF

8. Estimabl2 trial: Thyroidectomy without radioiodine in patients with low-risk thyroid cancer, 5 years of follow-up

Author

Lamartina, L., primary, Leboulleux, S., additional, Bournaud, C., additional, Chougnet, C., additional, Zerdoud, S., additional, Do Cao, C., additional, Catargi, B., additional, Dygai, I., additional, Kelly, A., additional, Barge, M.L., additional, Vera, P., additional, Rusu, D., additional, Schneegans, O., additional, Roux, J., additional, Klein, M., additional, Benisvy, D., additional, Eberle, M.C., additional, Bidault, S., additional, Nascimento, C., additional, Bastie, D., additional, Giraudet, A.L., additional, Bardet, S., additional, Le Moullec, N., additional, Roudaut, N., additional, Drui, D., additional, Godbert, Y., additional, Zalzali, M., additional, Drutel, A., additional, Morel, O., additional, Velayoudom, F.L., additional, Al Ghuzlan, A., additional, Schlumberger, M., additional, Buffet, C., additional, and Borget, I., additional

Published
2023
Full Text
View/download PDF

13. Facteurs pronostiques des carcinomes anaplasiques de la thyroïde durant la dernière décennie au sein du réseau ENDOCAN-TUTHYREF

Author

Jannin, A., primary, Giudici, F., additional, De La Fouchardiere, C., additional, Al Ghuzlan, A., additional, Wassermann, J., additional, Chougnet, C.N., additional, Drui, D., additional, Godbert, Y., additional, Illouz, F., additional, Bardet, S., additional, Dygai-Cochet, I., additional, Roudaut, N., additional, Batisse-Lignier, M., additional, Groussin, L., additional, Klein, M., additional, Zerdoud, S., additional, Lamartina, L., additional, Baudin, E., additional, Decaussin-Petrucci, M., additional, Leteurtre, E., additional, Borson-Chazot, F., additional, Do Cao, C., additional, Borget, I., additional, and Hadoux, J., additional

Published
2022
Full Text
View/download PDF

14. BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network

Author

De La Fouchardiere, C., primary, Jannin, A., additional, Giudici, F., additional, Wassermann, J., additional, Chougnet, C.N., additional, Drui, D., additional, Godbert, Y., additional, Illouz, F., additional, Bardet, S., additional, Dygai-Cochet, I., additional, Roudaut, N., additional, Batisse-Lignier, M., additional, Groussin, L., additional, Klein, M., additional, Zerdoud, S., additional, Lamartina, L., additional, Baudin, E., additional, Borson-Chazot, F., additional, Do Cao, C., additional, Borget, I., additional, and Hadoux, J., additional

Published
2022
Full Text
View/download PDF

15. 1647MO BRAF mutated anaplastic thyroid carcinoma: Clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real-life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network

Author

de la Fouchardiere, C., primary, Jannin, A., additional, Giudici, F., additional, Wassermann, J., additional, Chougnet, C., additional, Drui, D., additional, Godbert, Y., additional, Illouz, F., additional, Bardet, S., additional, Roudaut, N., additional, Batisse Lignier, M., additional, Groussin, L., additional, Klein, M., additional, Zerdoud, S., additional, Lamartina, L., additional, Baudin, E., additional, Borson-Chazot, F., additional, Do Cao, C., additional, Borget, I., additional, and Hadoux, J., additional

Published
2022
Full Text
View/download PDF

20. Computer Aided Imaging Analysis software for SPECT/CT protocol comparisons

Author

Jaudet, C, Corroyer-Dulmont, A, Weyts, K, Quak, E, Lasnon, C, Ciappuccini, R, Foucras, G, Savigny, Jf, Batalla, A, Bardet, S, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de médecine nucléaire [Baclesse, Caen], Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Interactions hôtes-agents pathogènes [Toulouse] (IHAP), Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), and Brunaud, Carole

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

CERVOXY; International audience

Published
2021

21. Generation of megawatt soliton at 1680 nm in very large mode area antiresonant fiber and application to three-photon microscopy

Author

Delahaye, H, primary, Hage, C-H, additional, Bardet, S M, additional, Tiliouine, I, additional, Granger, G, additional, Gaponov, D, additional, Lavoute, L, additional, Jossent, M, additional, Aleshkina, S, additional, Bubnov, M, additional, Salganskii, M, additional, Lipatov, D, additional, Guryanov, A, additional, Likhachev, M, additional, Louradour, F, additional, and Février, S, additional

Published
2021
Full Text
View/download PDF

23. Évaluation des patients avec carcinome médullaire thyroïdien en réponse prolongée au vandetanib dans le réseau français ENDOCAN – TUTHYREF

Author

Lasolle, H., Lamartina, L., Do Cao, C., Buffet, C., Schneegans, O., Gauduchon, T., Drui, D., Benisvy, D., Grunenwald, S., Godbert, Y., Bardet, S., Batisse-Lignier, M., Chougnet, C., Nascimento, C., Roudaut, N., Illouz, F., Sajous, C., Hadoux, J., Borget, I., and Borson-Chazot, F.

Abstract

Le vandetanib est indiqué en première ligne (L1) dans les carcinomes médullaires thyroïdiens (CMT) requérant un traitement systémique. Dans la littérature, la durée médiane de traitement est d’environ 20 mois, un quart des patients peuvent présenter une réponse prolongée.

Published
2024
Full Text
View/download PDF

28. Computer Aided Imaging Analysis software allow a reproducible and accurate Imaging protocol comparison

Author

Jaudet, C., Corroyer-Dulmont, A., Weyts, K., Quak, E., Lasnon, C., Ciappuccini, R., Foucras, G., Savigny, Jf., Batalla, A., Bardet, S., Brunaud, Carole, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Imagerie et Stratégies Thérapeutiques des pathologies Cérébrales et Tumorales (ISTCT), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Service de médecine nucléaire [Baclesse, Caen], Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Interactions hôtes-agents pathogènes [Toulouse] (IHAP), Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

CERVOXY; National audience

Published
2021

30. Hypothalamus

Author

Puelles, Luis, primary, Martinez-de-la-Torre, Margaret, additional, Bardet, S., additional, and Rubenstein, J.L.R., additional

Published
2012
Full Text
View/download PDF

33. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients

Author

Schlumberger, M, Hitzel, A, Toubert, M E., Corone, C, Troalen, F, Schlageter, M H., Claustrat, F, Koscielny, S, Taieb, D, Toubeau, M, Bonichon, F, Borson-Chazot, F, Leenhardt, L, Schvartz, C, Dejax, C, Brenot-Rossi, I, Torlontano, M, Tenenbaum, F, Bardet, S, Bussière, F, Girard, J J., Morel, O, Schneegans, O, Schlienger, J L., Prost, A, So, D, Archambeaud, F, Ricard, M, and Benhamou, E

Published
2007

39. Prise en charge d’un cancer thyroïdien pédiatrique de souche folliculaire en France : une enquête nationale du réseau TUTHYREF

Author

Dufresne, A., Verite, C., Zerdoud, S., Ansquer, C., Oliver-Petit, I., Borson-Chazot, F., Bardet, S., Ciappuccini, R., Roy, M., Lamartinia, L., and Haissaguerre, M.

Abstract

Les cancers thyroïdiens de souche folliculaire (CT) sont rares chez les enfants et les adolescents nécessitant une prise en charge experte multidisciplinaire conformément aux recommandations ETA 2022. Cette étude rétrospective multicentrique du réseau national TUTHYREF a pour objectif de décrire le parcours de soins actuel et le devenir de ces patients. 52 patients mineurs pris en charge pour un CT entre 2010 et 2022 ont été inclus ce jour avec un âge médian de 14 ans. 63 % des patients avaient un nodule Bethesda V ou IV ; 11 % Bethesda IV et 4 % Bethesda III. La chirurgie thyroïdienne était validée en RCP dans 31 % des cas, impliquant un pédiatre dans 35 % des cas et une consultation génétique dans 26 % des cas. 16 % des patients étaient opérés par un chirurgien pédiatrique. 88 % et 12 % des cancers étaient respectivement papillaires ou folliculaires. 40 % des patients présentaient une hypoparathyroïdie transitoire et 10 % une hypoparathyroïdie définitive. Après une thyroïdectomie totale dont 77 % avec un curage ganglionnaire, un traitement par iode radioactif était proposé à 98 % des patients, dont 58 % en sevrage et 42 % sous Thyrogen®, avec une Tg médiane au moment de l’iode à 4,8ng/mL et plusieurs cures pour 38 % des patients. Des métastases ganglionnaires et à distance étaient présentes chez 50 % et 9 % enfants. Après le traitement initial, 65 % des patients étaient d’emblée en rémission, 26 % présentaient une récidive locorégionale. Après un suivi médian de 3 ans, 93 % des patients étaient en rémission et 7 % en réponse biologique incomplète sans aucun décès.

Published
2024
Full Text
View/download PDF

41. Deauville score evaluationof PET2 positive patients included in the H10 trial

Author

Cottereau, Anne-Ségolène, Versari, A., Loft, A., Casasnovas, O., Bellei, M., Ricci, R., Bardet, S., Castagnoli, A., Brice, P., Raemaekers, J. M. M., Raveloarivahy, Tiana, van Zele, Emelie, Chartier, L, Vander Borght, T., Federico, M, Hutchings, Martin, Ricardi, Umberto, Meignan, M, Andre, M., AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Cochin [AP-HP], Santa Maria Nuova Hospital, Rigshospitalet [Copenhagen], Copenhagen University Hospital, Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Università degli Studi di Modena e Reggio Emilia (UNIMORE), The Lymphoma Academic Research Organisation [Lyon] (LYSARC), CHU Henri Mondor, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Ospedale Santo Stefano, Hopital Saint-Louis [AP-HP] (AP-HP), Radboud university [Nijmegen], European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU UCL Namur, University of Turin, LYSA Imaging (Créteil) (LYSA-IM), and université de Bourgogne, LNC

Subjects
Nuclear Medicine & Medical Imaging, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, Radiology, [SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine
Abstract

IF 7.704 (2017)Communication donnée lors du 31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Dusseldorf, Germany, du 13 au 17 octobre 2018; International audience

Published
2018

47. EP-1167: Indications for external beam radiotherapy in differentiated thyroid carcinoma: an expert consensus

Author

Blais, E., primary, Lagarde, P., additional, Henriques de Figueiredo, B., additional, Nicolescu-Catargi, B., additional, Schneegans, O., additional, Kelly, A., additional, Do Cao, C., additional, Lion, G., additional, Benisvy, D., additional, Zerdoud, S., additional, Bardet, S., additional, Chougnet, C., additional, Drui, D., additional, De la Fouchardiere, C., additional, Nascimento, C., additional, Leboulleux, S., additional, Troussier, I., additional, Thariat, J., additional, Maingon, P., additional, Bourhis, J., additional, Ozsahin, M., additional, and Godbert, Y., additional

Published
2018
Full Text
View/download PDF

48. Strategie per l’ablazione con radioiodio nei pazienti con carcinoma tiroideo a basso rischio

Author

Schlumberger, M., Catargi, B., Borget, I., Deandreis, D., Zerdoud, S., Bridji, B., Bardet, S., Leenhardt, L., Bastie, D., Schvartz, C., Vera, P., Morel, O., Benisvy, D., Bournaud, C., Bonichon, F., Dejax, C., Toubert, M. E., Leboulleux, S., Ricard, M., Benhamou, E., Centanni, Marco, Del Duca, Susanna, and Tumeurs de la Thyroïde Refractaires Network for the Essai Stimulation Ablation Equivalence Trial

Published
2012
Full Text
View/download PDF

49. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial

Author

Cottereau, A.S., Versari, A., Loft, A., Casasnovas, O., Bellei, M., Ricci, R., Bardet, S., Castagnoli, A., Brice, P., Raemaekers, J.M., Deau, B., Fortpied, C., Raveloarivahy, T., Zele, E. Van, Chartier, L., Borght, T. van der, Federico, M., Hutchings, M., Ricardi, U., Andre, M., Meignan, M., Cottereau, A.S., Versari, A., Loft, A., Casasnovas, O., Bellei, M., Ricci, R., Bardet, S., Castagnoli, A., Brice, P., Raemaekers, J.M., Deau, B., Fortpied, C., Raveloarivahy, T., Zele, E. Van, Chartier, L., Borght, T. van der, Federico, M., Hutchings, M., Ricardi, U., Andre, M., and Meignan, M.

Abstract

Item does not contain fulltext, We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P = .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm(3)) group (n = 46), respectively, vs 92% and 98% in the low-TMTV group (147+DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV147+DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well.

Published
2018

50. Élastographie par ondes de cisaillement et nodules thyroïdiens à cytologie indéterminée : résultats d’une étude prospective bicentrique

Author

Bardet, S., primary, Ciappuccini, R., additional, Pellot-Barakat, C., additional, Monpeyssen, H., additional, Michels, J.J., additional, Tissier, F., additional, Blanchard, D., additional, Menegaux, F., additional, De Raucourt, D., additional, Lefort, M., additional, Reznik, Y., additional, Rouxel, A., additional, Heutte, N., additional, Brenac, F., additional, Leconte, A., additional, Buffet, C., additional, Clarisse, B., additional, and Leenhardt, L., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results